|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choi S and Myers JN: Molecular
pathogenesis of oral squamous cell carcinoma: Implications for
therapy. J Dent Res. 87:14–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abram MH, van Heerden WF, Rheeder P,
Girdler-Brown BV and van Zyl AW: Epidemiology of oral squamous cell
carcinoma. SADJ. 67:550–553. 2012.PubMed/NCBI
|
|
4
|
Fuller CD, Wang SJ, Thomas CR Jr, Hoffman
HT, Weber RS and Rosenthal DI: Conditional survival in head and
neck squamous cell carcinoma: Results from the SEER dataset
1973–1998. Cancer. 109:1331–1343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aldinger KA, Lehmann OJ, Hudgins L,
Chizhikov VV, Bassuk AG, Ades LC, Krantz ID, Dobyns WB and Millen
KJ: FOXC1 is required for normal cerebellar development and is a
major contributor to chromosome 6p25.3 Dandy-Walker malformation.
Nat Genet. 41:1037–1042. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin YJ, Shyu WC, Chang CW, Wang CC, Wu CP,
Lee HT, Chen LJ and Hsieh CH: Tumor hypoxia regulates forkhead box
C1 to promote lung cancer progression. Theranostics. 7:1177–1191.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Chai L, Ji Q, Cheng R, Wang J and
Han S: Forkhead box protein C1 promotes cell proliferation and
invasion in human cervical cancer. Mol Med R. 17:4392–4398.
2018.
|
|
8
|
Ou-Yang L, Xiao SJ, Liu P, Yi SJ, Zhang
XL, Ou-Yang S, Tan SK and Lei X: Forkhead box C1 induces
epithelial-mesenchymal transition and is a potential therapeutic
target in nasopharyngeal carcinoma. Mol Med Rep. 12:8003–8009.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dai L, Cui X, Zhang X, Cheng L, Liu Y,
Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits
angiogenesis and tumour growth of human colon cancer through
directly targeting ceruloplasmin. Nat Commun. 7:119962016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Berry FB, Saleem RA and Walter MA: FOXC1
transcriptional regulation is mediated by N- and C-terminal
activation domains and contains a phosphorylated transcriptional
inhibitory domain. J Biol Chem. 277:10292–10297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xia L, Huang W, Tian D, Zhu H, Qi X, Chen
Z, Zhang Y, Hu H, Fan D, Nie Y and Wu K: Overexpression of forkhead
box C1 promotes tumor metastasis and indicates poor prognosis in
hepatocellular carcinoma. Hepatology. 57:610–624. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu ZY, Ding SM, Zhou L, Xie HY, Chen KJ,
Zhang W, Xing CY, Guo HJ and Zheng SS: FOXC1 contributes to
microvascular invasion in primary hepatocellular carcinoma via
regulating epithelial-mesenchymal transition. Int J Biol Sci.
8:1130–1141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang W, Chen Z, Zhang L, Tian D, Wang D,
Fan D, Wu K and Xia L: Interleukin-8 induces expression of FOXC1 to
promote transactivation of CXCR1 and CCL2 in hepatocellular
carcinoma cell lines and formation of metastases in mice.
Gastroenterology. 149:1053–1067.e1014. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Gu F, Liu CY, Wang RJ, Li J and Xu
JY: High level of FOXC1 expression is associated with poor
prognosis in pancreatic ductal adenocarcinoma. Tumour Biol.
34:853–858. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu Y, Shao QS, Yao HB, Jin Y, Ma YY and
Jia LH: Overexpression of FOXC1 correlates with poor prognosis in
gastric cancer patients. Histopathology. 64:963–970. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishimura DY, Searby CC, Alward WL, Walton
D, Craig JE, Mackey DA, Kawase K, Kanis AB, Patil SR, Stone EM and
Sheffield VC: A spectrum of FOXC1 mutations suggests gene dosage as
a mechanism for developmental defects of the anterior chamber of
the eye. Am J Hum Genet. 68:364–372. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanwar M, Kumar M, Dada T, Sihota R and
Dada R: MYOC and FOXC1 gene analysis in primary congenital
glaucoma. Mol Vis. 16:1996–2006. 2010.PubMed/NCBI
|
|
19
|
Hayashi H and Kume T: Forkhead
transcription factors regulate expression of the chemokine receptor
CXCR4 in endothelial cells and CXCL12-induced cell migration.
Biochem Biophys Res Commun. 367:584–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ray PS, Wang J, Qu Y, Sim MS, Shamonki J,
Bagaria SP, Ye X, Liu B, Elashoff D, Hoon DS, et al: FOXC1 is a
potential prognostic biomarker with functional significance in
basal-like breast cancer. Cancer Res. 70:3870–3876. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou M, Ye Z, Gu Y, Tian B, Wu B and Li J:
Genomic analysis of drug resistant pancreatic cancer cell line by
combining long non-coding RNA and mRNA expression profling. Int J
Clin Exp Pathol. 8:38–52. 2015.PubMed/NCBI
|
|
22
|
Strizzi L, Bianco C, Normanno N, Seno M,
Wechselberger C, Wallace-Jones B, Khan NI, Hirota M, Sun Y,
Sanicola M and Salomon DS: Epithelial mesenchymal transition is a
characteristic of hyperplasias and tumors in mammary gland from
MMTV-Cripto-1 transgenic mice. J Cell Physiol. 201:266–276. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lambers E, Arnone B, Fatima A, Qin G,
Wasserstrom JA and Kume T: Foxc1 regulates early cardiomyogenesis
and functional properties of embryonic stem cell derived
cardiomyocytes. Stem Cells. 34:1487–1500. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin Z, Sun L, Chen W, Liu B, Wang Y, Fan
S, Li Y and Li J: miR-639 regulates transforming growth factor
beta-induced epithelial-mesenchymal transition in human tongue
cancer cells by targeting FOXC1. Cancer Sci. 105:1288–1298. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Medina-Trillo C, Aroca-Aguilar JD,
Ferre-Fernandez JJ, Méndez-Hernández CD, Morales L, García-Feijoo J
and Escribano J: The role of hsa-miR-548l dysregulation as a
putative modifier factor for glaucoma-associated FOXC1 mutations.
Microrna. 4:50–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin Y, Han B, Chen J, Wiedemeyer R,
Orsulic S, Bose S, Zhang X, Karlan BY, Giuliano AE, Cui Y and Cui
X: FOXC1 is a critical mediator of EGFR function in human
basal-like breast cancer. Ann Surg Oncol. 21 Suppl 4:S758–S766.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hopkins A, Mirzayans F and Berry F: Foxc1
expression in early osteogenic differentiation is regulated by
BMP4-SMAD activity. J Cell Biochem. 117:1707–1717. 2016. View Article : Google Scholar : PubMed/NCBI
|
